Keystone Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2011
Here are the related meetings in 2020:
MEETING CANCELLED: PI3-Kinase and PTEN at the Interface of Cell Growth, Vesicular Trafficking and Disease (E1)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
PI 3-Kinase Signaling Pathways (X2)
Organizer(s) Bart Vanhaesebroeck, Sabina Cosulich and Ramon Parsons
February 13—18, 2011
Keystone Resort • Keystone, CO USA
Abstract Deadline: Oct 14, 2010
Late Abstract Deadline: Nov 18, 2010
Scholarship Deadline: Oct 14, 2010
Early Registration Deadline: Dec 14, 2010
Sponsored by Bayer USA Foundation and Genentech, Inc.
Joint Meeting:
Inositide Signaling in Pharmacology and Disease (X1)
Summary of Meeting:
The PI 3-kinase signaling pathway controls multiple physiological processes including cell growth, cell proliferation and cell movement. Dysregulation of this pathway in cancer, inflammation and heart disease has led to the emergence of PI 3-kinase as a promising therapeutic target. One of the most exciting developments in this field is the development of new PI 3-kinase inhibitors that are currently entering the clinic. The balance between modulating PI 3-kinase activity in a pathophysiological setting, while avoiding unwanted side effects, is the subject of intense debate. In addition, as PI 3-kinase is a member of a multigene family, the rationale for inhibiting individual isoforms or multiple isoforms of PI 3-kinase is constantly changing. This meeting aims to bring together scientists and clinicians from academia and industry to discuss the opportunities and liabilities of targeting the PI 3-kinase pathway in disease, drawing on human pathophysiology and genetics, mouse models and (pre)clinical data with new PI 3-kinase inhibitors.
View Scholarships/Awards
The PI 3-kinase signaling pathway controls multiple physiological processes including cell growth, cell proliferation and cell movement. Dysregulation of this pathway in cancer, inflammation and heart disease has led to the emergence of PI 3-kinase as a promising therapeutic target. One of the most exciting developments in this field is the development of new PI 3-kinase inhibitors that are currently entering the clinic. The balance between modulating PI 3-kinase activity in a pathophysiological setting, while avoiding unwanted side effects, is the subject of intense debate. In addition, as PI 3-kinase is a member of a multigene family, the rationale for inhibiting individual isoforms or multiple isoforms of PI 3-kinase is constantly changing. This meeting aims to bring together scientists and clinicians from academia and industry to discuss the opportunities and liabilities of targeting the PI 3-kinase pathway in disease, drawing on human pathophysiology and genetics, mouse models and (pre)clinical data with new PI 3-kinase inhibitors.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
SUNDAY, FEBRUARY 13
MONDAY, FEBRUARY 14
TUESDAY, FEBRUARY 15
WEDNESDAY, FEBRUARY 16
THURSDAY, FEBRUARY 17
FRIDAY, FEBRUARY 18
Conference Program Print | View meeting in 12 hr (am/pm) time
SUNDAY, FEBRUARY 13
19:15—19:30
Welcome Address (Joint, on behalf of both meetings)
*
Sabina C. Cosulich,
AstraZeneca Oncology, UK
19:30—21:30
Keynote Session (Joint)
*
Robin F. Irvine,
University of Cambridge, UK
Robert H. Michell,
University of Birmingham, UK
Inositol Phospholipids: Origins and Evolution of Functions
Inositol Phospholipids: Origins and Evolution of Functions
Lewis C. Cantley,
Weill Cornell Medicine, USA
The Role of Phosphoinositides in Human Disease
The Role of Phosphoinositides in Human Disease
08:00—11:15
Phosphoinositide 3-Kinase Signaling in Disease: Class 1 PI3Ks (Joint)
Bart Vanhaesebroeck,
University College London, Cancer Institute, UK
Direct and Indirect Actions of PI3K in Cancer
Direct and Indirect Actions of PI3K in Cancer
Roger L. Williams,
Medical Research Council, UK
Structural Insights into PI3K Isoform-Specific Signaling
Structural Insights into PI3K Isoform-Specific Signaling
Len R. Stephens,
Babraham Institute, UK
Mass Spectrometry based Measurement of PtdIns(3,4,5)P3 Molecular Species
Mass Spectrometry based Measurement of PtdIns(3,4,5)P3 Molecular Species
Ana Clara Carrera,
Centro Nacional Biotechnologia/CSIC, Spain
PI3K Isoforms Function in Inflammation and Cancer
PI3K Isoforms Function in Inflammation and Cancer
Katarina Ejeskär,
Probion Innovation Sweden, Sweden
Short Talk: p37delta, a New Isoform of PI3K p110delta, Increases Cell Proliferation in vitro and in vivo
Short Talk: p37delta, a New Isoform of PI3K p110delta, Increases Cell Proliferation in vitro and in vivo
Deborah H. Anderson,
Saskatchewan Cancer Agency, Canada
Short Talk: Regulation of PTEN by the p85 Subunit of Phosphatidylinositol 3-Kinase (PI3K)
Short Talk: Regulation of PTEN by the p85 Subunit of Phosphatidylinositol 3-Kinase (PI3K)
17:00—19:00
PI 3-Kinase and Signaling: Non-Class I PI3Ks
Takehiko Sasaki,
Tokyo Medical and Dental University, Japan
Role for 3-Phosphoinositide Metabolism in vivo
Role for 3-Phosphoinositide Metabolism in vivo
Jonathan M. Backer,
Albert Einstein College of Medicine, USA
Regulation of Class I and Class III PI 3-Kinases
Regulation of Class I and Class III PI 3-Kinases
David Harris,
Lexicon Pharmaceuticals, Inc., USA
Short Talk: Requirement for the Class II Phosphoinositide 3-Kinase C2alpha in Maintenance of Glomerular Structure and Function
Short Talk: Requirement for the Class II Phosphoinositide 3-Kinase C2alpha in Maintenance of Glomerular Structure and Function
Tania Maffucci,
Queen Mary University of London, UK
Short Talk: Role of Class II Phosphoinositide 3-Kinase alpha in Diabetes
Short Talk: Role of Class II Phosphoinositide 3-Kinase alpha in Diabetes
Frederic A. Meunier,
Queensland Brain Institute, Australia
Short Talk: Fine-Tuning of Neuroexocytosis by Two Members of the PI3-Kinase Family: Type I PI3Kdelta and Type II PI3K-C2alpha
Short Talk: Fine-Tuning of Neuroexocytosis by Two Members of the PI3-Kinase Family: Type I PI3Kdelta and Type II PI3K-C2alpha
17:00—19:00
Other Phosphoinositide Kinases
Nullin Divecha,
University of Southampton, UK
PIP2 Synthesis
PIP2 Synthesis
Robin F. Irvine,
University of Cambridge, UK
Inositide Kinases and their Products - A Matter of Location
Inositide Kinases and their Products - A Matter of Location
Scott D. Emr,
Cornell University, USA
Phosphoinositide Signaling and Membrane Traffic: Regulation of PIP Phosphatases
Phosphoinositide Signaling and Membrane Traffic: Regulation of PIP Phosphatases
Assia Shisheva,
Wayne State University School of Medicine, USA
Short Talk: PIKfyve-ArPIKfyve-Sac3 Protein Machinery to Orchestrate Coordinated Regulation of PI(3,5)P2 Synthesis and Turnover in Mammalian Cells
Short Talk: PIKfyve-ArPIKfyve-Sac3 Protein Machinery to Orchestrate Coordinated Regulation of PI(3,5)P2 Synthesis and Turnover in Mammalian Cells
08:00—11:15
Downstream of PI 3-Kinase: Akt, mTOR and Metabolism
*
Neal Rosen,
Memorial Sloan-Kettering Cancer Center, USA
Alex Toker,
Beth Israel Deaconess Medical Center, USA
Akt Isoform Specificity in Breast Cancer Cell Signaling
Akt Isoform Specificity in Breast Cancer Cell Signaling
Brendan D. Manning,
Harvard School of Public Health, USA
mTOR Controls Cellular Metabolism Downstream of PI3K
mTOR Controls Cellular Metabolism Downstream of PI3K
Joan S. Brugge,
Harvard Medical School, USA
PI3K Pathway in Tumor Cell Metabolism and Matrix Control
PI3K Pathway in Tumor Cell Metabolism and Matrix Control
Craig B. Thompson,
Memorial Sloan Kettering Cancer Center, USA
Activation of the PI3K Pathway is Essential for Cell Autonomous Nutrient Uptake
Activation of the PI3K Pathway is Essential for Cell Autonomous Nutrient Uptake
James Brugarolas,
UT Southwestern Medical Center, USA
Short Talk: Regulation of V-ATPases and Endocytosis by mTORC1
Short Talk: Regulation of V-ATPases and Endocytosis by mTORC1
David A. Fruman,
University of California, Irvine, USA
Short Talk: TOR Inhibitors Promote Activity of FOXO Transcription Factors in Lymphocytes
Short Talk: TOR Inhibitors Promote Activity of FOXO Transcription Factors in Lymphocytes
08:00—11:15
Phosphoinositides in Signaling and Disease
Bernard Payrastre,
INSERM, France
Phosphoinositide Signaling and Diseases: A Role for PtdIns5P
Phosphoinositide Signaling and Diseases: A Role for PtdIns5P
Peter J. Cullen,
University of Bristol, UK
Phosphoinositides and the Regulation of the Endo-Lysosomal Network
Phosphoinositides and the Regulation of the Endo-Lysosomal Network
Tamas Balla,
NICHD, National Institutes of Health, USA
Detection and Rapid Manipulation of Phosphoinositides in Living Cells
Detection and Rapid Manipulation of Phosphoinositides in Living Cells
Amy Kiger,
University of California, San Diego, USA
Short Talk: Coordinated PI3KC2/Mtm Phosphoinositide Regulation and Rab activity in Membrane Trafficking and Disease
Short Talk: Coordinated PI3KC2/Mtm Phosphoinositide Regulation and Rab activity in Membrane Trafficking and Disease
Xinjiang Cai,
Skirball Institute of Biomolecular Medicine, NYU Medical Center, USA
Short Talk: Negative Regulation of CD4 T Cell Activation by Tripartite Motif Containing Protein 27 via the Ubiquitination and Inhibition of the Class II Phosphatidylinositol 3 Kinase C2-beta
Short Talk: Negative Regulation of CD4 T Cell Activation by Tripartite Motif Containing Protein 27 via the Ubiquitination and Inhibition of the Class II Phosphatidylinositol 3 Kinase C2-beta
14:30—16:30
Workshop: Novel Experimental Approaches to Investigate Phosphoinositide Signalling
*
Tamas Balla,
NICHD, National Institutes of Health, USA
Thomas Masters,
Mechanobiology Institute, Singapore
Evidence for a Fence that Impedes the Diffusion of Phosphatidylinositol 4,5-Bisphosphate (PIP2) Out of the Forming Phagosomes of Macrophages
Evidence for a Fence that Impedes the Diffusion of Phosphatidylinositol 4,5-Bisphosphate (PIP2) Out of the Forming Phagosomes of Macrophages
Dominik Oliver,
University of Marburg, Germany
Voltage Sensitive Phosphatases as Tools for Characterizing Phosphoinositide Sensors and Effectors
Voltage Sensitive Phosphatases as Tools for Characterizing Phosphoinositide Sensors and Effectors
Qisheng Zhang,
University of North Carolina at Chapel Hill, USA
Small Molecule Reporters and Modulators for Mammalian Phospholipase C Isozymes
Small Molecule Reporters and Modulators for Mammalian Phospholipase C Isozymes
Wonhwa Cho,
University of Illinois at Chicago, USA
In Situ Quantitative Imaging of Phosphoinositides
In Situ Quantitative Imaging of Phosphoinositides
Gerry Hammond,
University of Cambridge, UK
Dissecting the Roles of Plasma Membrane PtdIns4P and PtdIns(4,5)P2
Dissecting the Roles of Plasma Membrane PtdIns4P and PtdIns(4,5)P2
Lucia E. Rameh,
Boston Biomedical Research Institute, USA
A New Mechanism for Regulating the PI-5-P Pathway for PI-4,5-P2 Synthesis in Response to Changes in the Extracellular Environment
A New Mechanism for Regulating the PI-5-P Pathway for PI-4,5-P2 Synthesis in Response to Changes in the Extracellular Environment
Jeffrey R. Peterson,
Fox Chase Cancer Center, USA
Phosphoinositides are Essential Co-Activators for p21-Activated Kinase 1 (Pak1)
Phosphoinositides are Essential Co-Activators for p21-Activated Kinase 1 (Pak1)
Michael J. Schell,
Uniformed Services University, USA
F-Actin Binding by Inositol Trisphosphate 3-Kinase: A Recent Evolutionary Elaboration for Localized IP3 Control and Structural Plasticity in Dendritic Spines
F-Actin Binding by Inositol Trisphosphate 3-Kinase: A Recent Evolutionary Elaboration for Localized IP3 Control and Structural Plasticity in Dendritic Spines
17:00—19:00
Therapeutic Strategies in the PI 3-Kinase Pathway
*
Sabina C. Cosulich,
AstraZeneca Oncology, UK
Christian Rommel,
F. Hoffmann-La Roche Ltd, Switzerland
Targeting PI3Kalpha and TORC1/2 Alone or in Combination for the Treatment of Solid Tumor
Targeting PI3Kalpha and TORC1/2 Alone or in Combination for the Treatment of Solid Tumor
Neal Rosen,
Memorial Sloan-Kettering Cancer Center, USA
PI3K Pathways in Cancer, Mechanistic Insights
PI3K Pathways in Cancer, Mechanistic Insights
Jeffrey A. Engelman,
Novartis Institutes for BioMedical Research, USA
Optimizing PI3K Targeting in Cancer, Mechanistic Insights
Optimizing PI3K Targeting in Cancer, Mechanistic Insights
Kyle A. Edgar,
Genentech, Inc., USA
Short Talk: PI3K Pathway Signaling Promotes an Invasive Phenotype that is Independent of Akt
Short Talk: PI3K Pathway Signaling Promotes an Invasive Phenotype that is Independent of Akt
17:00—19:00
Phosphoinositide Metabolism
*
Nullin Divecha,
University of Southampton, UK
Pietro V. De Camilli,
Yale University School of Medicine, USA
Phosphoinositide Metabolism in Endocytic Membrane Traffic
Phosphoinositide Metabolism in Endocytic Membrane Traffic
Shamshad Cockcroft,
University College London, UK
Phosphatidylinositol Transfer Proteins: Is Phosphatidylinositol Transfer or Binding the Key to Function Phosphatidylinositol Transfer Proteins: Is Phosphatidylinositol Transfer Activity Required for Function?
Phosphatidylinositol Transfer Proteins: Is Phosphatidylinositol Transfer or Binding the Key to Function Phosphatidylinositol Transfer Proteins: Is Phosphatidylinositol Transfer Activity Required for Function?
Lois S. Weisman,
University of Michigan, USA
Roles of Phosphatidylinositol 3,5 bis Phosphate, a Lipid with Unexpected Links to Neurodegenerative Disease
Roles of Phosphatidylinositol 3,5 bis Phosphate, a Lipid with Unexpected Links to Neurodegenerative Disease
Dave Bridges,
University of Michigan, USA
Short Talk: Endolysosomal Phosphatidylinositides and the Regulation of TORC1 Localization and Function
Short Talk: Endolysosomal Phosphatidylinositides and the Regulation of TORC1 Localization and Function
08:00—11:15
Phosphoinositide Phosphatases (Joint)
*
Lewis C. Cantley,
Weill Cornell Medicine, USA
*
Bernard Payrastre,
INSERM, France
Ramon Parsons,
Icahn School of Medicine at Mount Sinai, USA
The Role of PTEN Signaling Perturbations in Cancer and in Targeted Therapy
The Role of PTEN Signaling Perturbations in Cancer and in Targeted Therapy
Jocelyn Laporte,
Institute of Genetics and Molecular and Cellular Biology, France
Myotubularins and Associated Neuromuscular Diseases
Myotubularins and Associated Neuromuscular Diseases
Stéphane Schurmans,
Universite de Liège, Belgium
Functional Characterization of PI 5-Phosphatases and IP 3-Kinases in Mice
Functional Characterization of PI 5-Phosphatases and IP 3-Kinases in Mice
Pier Paolo Pandolfi,
Beth Israel Deaconess Medical Center, Harvard Medical School, USA
The Unanticipated Role of an Extended miRNA Proto-Oncogenic Network in the Modulation of PTEN-PI3K Signalling Output
The Unanticipated Role of an Extended miRNA Proto-Oncogenic Network in the Modulation of PTEN-PI3K Signalling Output
Christina Anne Mitchell,
Monash University, Australia
Short Talk: INPP4B – a Putative Tumour Suppressor in Human Breast Cancer
Short Talk: INPP4B – a Putative Tumour Suppressor in Human Breast Cancer
Wayne Bowden,
Florida International University College of Medicine, USA
Short Talk: Inositol Polyphosphate 4-Phosphatase Type II, INPP4B, is an Androgen Induced Tumor Suppressor in Prostate Cancer
Short Talk: Inositol Polyphosphate 4-Phosphatase Type II, INPP4B, is an Androgen Induced Tumor Suppressor in Prostate Cancer
17:00—19:00
Mouse Models of Class I PI3K in Disease
*
Len R. Stephens,
Babraham Institute, UK
Emilio Hirsch,
Fondazione per la Ricerca Biomedica – ONLUS, Italy
p110gamma in Immunity, Inflammation and Cardiac Context
p110gamma in Immunity, Inflammation and Cardiac Context
Jean J. Zhao,
Dana-Farber Cancer Institute, USA
Targeting PI3K in Cancer, Mechanistic Insights from Genetic Mouse Models
Targeting PI3K in Cancer, Mechanistic Insights from Genetic Mouse Models
17:00—19:00
Inositol Phosphates Signaling
Lucio Cocco,
University of Bologna, Italy
Nuclear Inositide Signaling (PI-PLCbeta1: from Bench to Clinics)
Nuclear Inositide Signaling (PI-PLCbeta1: from Bench to Clinics)
John Condeelis,
Albert Einstein College of Medicine, USA
Phosphoinositol Regulation of Breast Tumor Cell Chemotaxis and Metastasis
Phosphoinositol Regulation of Breast Tumor Cell Chemotaxis and Metastasis
Chris Noakes,
University of Manchester, UK
Short Talk: The PH Domain Proteins IPIP27A and B (Ses1/2) Link OCRL1 to Receptor Recycling in the Endocytic Pathway
Short Talk: The PH Domain Proteins IPIP27A and B (Ses1/2) Link OCRL1 to Receptor Recycling in the Endocytic Pathway
08:00—11:00
PI 3-Kinase Pathway Inhibitors – Preclinical and Clinical Studies I
Kevan M. Shokat,
University of California, San Francisco, USA
Chemical Genetic Investigations of Protein and Lipid Kinase Signaling
Chemical Genetic Investigations of Protein and Lipid Kinase Signaling
Neill A. Giese,
, USA
Targeting PI3K Delta: A New Paradigm for the Treatment of B Cell Malignancies that Involves the Tumor Cell and it’s Microenvironment
Targeting PI3K Delta: A New Paradigm for the Treatment of B Cell Malignancies that Involves the Tumor Cell and it’s Microenvironment
David Finlay,
School of Life Sciences, University of Dundee, Scotland
Akt is dispensable for a T Cell Nutrient Uptake and Metabolism
Akt is dispensable for a T Cell Nutrient Uptake and Metabolism
Gordon B. Mills,
University of Texas MD Anderson Cancer Center, USA
A Systems Biology Approach to Monitor the PI3K Pathway
A Systems Biology Approach to Monitor the PI3K Pathway
Jordi Rodon,
Vall d'hebron University Hospital, Spain
Short Talk: Strategies for Selecting Patients with Tumors Harboring Alterations in the pI3K Pathway in Early Development of PI3K/akt/mTOR Inhibitors
Short Talk: Strategies for Selecting Patients with Tumors Harboring Alterations in the pI3K Pathway in Early Development of PI3K/akt/mTOR Inhibitors
Augustin Amour,
GlaxoSmithKline, UK
Short Talk: PI3Kdelta Inhibition: A Future Paradigm for the Inhaled Therapy of Asthma?
Short Talk: PI3Kdelta Inhibition: A Future Paradigm for the Inhaled Therapy of Asthma?
08:00—11:00
Inositides and Ion Channels
*
Shamshad Cockcroft,
University College London, UK
Bertil Hille,
University of Washington, USA
PIP2 is a Necessary Cofactor for Ion Channel Function: Biophysical Studies of Phosphoinositides in Living Cells
PIP2 is a Necessary Cofactor for Ion Channel Function: Biophysical Studies of Phosphoinositides in Living Cells
Victoria M. Bolotina,
Boston Medical Center, USA
Store-Operated Channels: What Makes Them Tick?
Store-Operated Channels: What Makes Them Tick?
James W. Putney, Jr.,
NIEHS, National Institutes of Health, USA
Regulation and Physiological Function of Store-Operated Calcium Entry
Regulation and Physiological Function of Store-Operated Calcium Entry
Ivan F. Gonzalez,
University of Washington, USA
Short Talk: Phosphoinositide Regulation of TRPV1 Sensitization during Inflammatory Hyperalgesia
Short Talk: Phosphoinositide Regulation of TRPV1 Sensitization during Inflammatory Hyperalgesia
Yuxin Mao,
Cornell University, USA
Short Talk: Crystal Structure of the Yeast Sac1: Implications for Its Phosphoinositide Phosphatase Function
Short Talk: Crystal Structure of the Yeast Sac1: Implications for Its Phosphoinositide Phosphatase Function
Peter Mayinger,
Oregon Health and Science University, USA
Short Talk: Metabolic Control of Phosphoinositide Phosphatase Sac1 via the HOG MAP Kinase Pathway and Calcineurin
Short Talk: Metabolic Control of Phosphoinositide Phosphatase Sac1 via the HOG MAP Kinase Pathway and Calcineurin
14:30—16:30
Workshop: Experience with PI 3-Kinase Inhibitors in the Clinic
Details to be Announced
*
José Baselga,
Memorial Sloan-Kettering Cancer Center, USA
17:00—19:00
PI 3-Kinase Pathway Inhibitors – Clinical Studies II
*
Lori Friedman,
ORIC Pharmaceuticals, USA
Langdon Miller,
Calistoga Pharmaceuticals Inc, USA
CAL-101 Inhibition of PI3K-delta Demonstrates Clinical and Pharmacodynamic Activity as a New Therapeutic Approach to Lymphoid Malignancies
CAL-101 Inhibition of PI3K-delta Demonstrates Clinical and Pharmacodynamic Activity as a New Therapeutic Approach to Lymphoid Malignancies
José Baselga,
Memorial Sloan-Kettering Cancer Center, USA
Ongoing Clinical Studies with PI3K Inhibitors in Cancer Patients
Ongoing Clinical Studies with PI3K Inhibitors in Cancer Patients
Mika Derynck,
Genentech, Inc., USA
Clinical Development Strategies of PI3K/mTOR Inhibitors
Clinical Development Strategies of PI3K/mTOR Inhibitors
Jeffrey J. Wallin,
Genentech, Inc., USA
Short Talk: Mutant PIK3CA Increases Microtubule Levels and Promotes Resistance to Anti-Mitotic Chemotherapy Drugs
Short Talk: Mutant PIK3CA Increases Microtubule Levels and Promotes Resistance to Anti-Mitotic Chemotherapy Drugs
17:00—19:00
Inositol Polyphosphates Signaling
Adolfo Saiardi,
University College London, UK
Are Inositol Pyrophosphates Signaling Molecules?
Are Inositol Pyrophosphates Signaling Molecules?
Susan R. Wente,
Vanderbilt University Medical Center, USA
Little Things that do a lot: Inositol Polyphosphates in DNA Repair
Little Things that do a lot: Inositol Polyphosphates in DNA Repair
Les A. Hanakahi,
University of Illinois at Chicago, Rockford Campus, USA
Short Talk: Inositol Polyphosphates: Effect on PI3K-Related Protein Kinase Substrate Selection
Short Talk: Inositol Polyphosphates: Effect on PI3K-Related Protein Kinase Substrate Selection
19:00—19:15
Concluding Remarks
*
Ramon Parsons,
Icahn School of Medicine at Mount Sinai, USA
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
|
Genentech, Inc. |
|
|
Genentech, Inc. |
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
|
Portland Press Ltd |
|
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
